ID17149A - Senyawa baru 2,3 tersubstitusi-4 (3h)-kuinazolinon - Google Patents

Senyawa baru 2,3 tersubstitusi-4 (3h)-kuinazolinon

Info

Publication number
ID17149A
ID17149A IDP971603A ID971603A ID17149A ID 17149 A ID17149 A ID 17149A ID P971603 A IDP971603 A ID P971603A ID 971603 A ID971603 A ID 971603A ID 17149 A ID17149 A ID 17149A
Authority
ID
Indonesia
Prior art keywords
kuinazolinon
substituted
new compounds
compounds
new
Prior art date
Application number
IDP971603A
Other languages
English (en)
Inventor
Mark L Elliot
Willard M Welch Jr
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ID17149A publication Critical patent/ID17149A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Paints Or Removers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IDP971603A 1996-05-15 1997-05-14 Senyawa baru 2,3 tersubstitusi-4 (3h)-kuinazolinon ID17149A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1773896P 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
ID17149A true ID17149A (id) 1997-12-04

Family

ID=21784266

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP971603A ID17149A (id) 1996-05-15 1997-05-14 Senyawa baru 2,3 tersubstitusi-4 (3h)-kuinazolinon

Country Status (39)

Country Link
US (1) US6303615B1 (id)
EP (1) EP0901487B9 (id)
JP (1) JP3241388B2 (id)
KR (1) KR100375155B1 (id)
CN (2) CN1103772C (id)
AP (1) AP1148A (id)
AR (1) AR007118A1 (id)
AT (1) ATE242232T1 (id)
AU (1) AU730503B2 (id)
BG (1) BG102999A (id)
BR (1) BR9709085A (id)
CA (1) CA2252907C (id)
CZ (1) CZ295565B6 (id)
DE (1) DE69722613T2 (id)
DK (1) DK0901487T3 (id)
DZ (1) DZ2237A1 (id)
EA (1) EA002905B1 (id)
ES (1) ES2198546T3 (id)
GT (1) GT199700049A (id)
HK (1) HK1019607A1 (id)
HN (1) HN1997000052A (id)
HR (1) HRP970261B1 (id)
HU (1) HUP9902148A3 (id)
ID (1) ID17149A (id)
IL (1) IL126589A (id)
IS (1) IS4881A (id)
MA (1) MA26430A1 (id)
NO (1) NO985293L (id)
OA (1) OA10918A (id)
PL (1) PL330042A1 (id)
PT (1) PT901487E (id)
SI (1) SI0901487T1 (id)
SK (1) SK284108B6 (id)
TN (1) TNSN97087A1 (id)
TR (1) TR199802296T2 (id)
TW (1) TW539675B (id)
WO (1) WO1997043276A1 (id)
YU (1) YU19197A (id)
ZA (1) ZA974156B (id)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3299990B2 (ja) * 1997-02-28 2002-07-08 ファイザー・プロダクツ・インク 神経変性状態およびｃｎｓ外傷関連状態の処置のための３−ヘテロアリール−４（３ｈ）−キナゾリノン類のアトロプ異性体
KR100358636B1 (ko) * 1997-02-28 2002-10-31 화이자 프로덕츠 인코포레이티드 3-아릴-4(3에이치)-퀴나졸리논의 회전장애이성질체 및 에이엠피에이-수용체 길항물질로서 그의 용도
US6060479A (en) * 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
EP0900567A3 (en) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
TWI258472B (en) * 1999-02-15 2006-07-21 Eisai Co Ltd Heterodiazinone derivatives
US6890930B1 (en) * 1999-09-28 2005-05-10 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1300396B1 (en) 2000-06-12 2009-01-14 Eisai R&D Management Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
WO2003043961A2 (en) * 2001-11-19 2003-05-30 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US7211580B2 (en) * 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
HUE030950T2 (en) 2004-05-13 2017-06-28 Icos Corp Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
WO2007056124A2 (en) * 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
EP2079739A2 (en) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008140750A1 (en) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
CN104211684A (zh) * 2007-09-26 2014-12-17 细胞基因公司 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法
MY153733A (en) 2008-01-30 2015-03-13 Shin Poong Pharmaceutical Co Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
CA3092449A1 (en) 2008-11-13 2010-05-20 Gilead Calistoga Llc Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
ES2548253T3 (es) 2009-04-20 2015-10-15 Gilead Calistoga Llc Métodos para el tratamiento de tumores sólidos
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
US9216177B2 (en) 2011-02-28 2015-12-22 Drexel University Small molecular inhibitors of RAD51 recombinase and methods thereof
PE20141792A1 (es) 2012-03-05 2014-12-07 Gilead Calistoga Llc Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
CA2934531C (en) 2013-12-20 2020-02-25 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
EP3083623A1 (en) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
CN106459005A (zh) 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
CN113226286B (zh) 2018-12-14 2024-08-20 卫材R&D管理有限公司 1,2-二氢吡啶化合物的水基药物制剂
CN115335050B (zh) 2020-01-29 2024-05-17 卡玛瑞制药有限公司 用于治疗皮肤病症的化合物和组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
GB1298603A (en) 1970-04-06 1972-12-06 Karamchand Premchand Private Quinazolinone derivatives
AU543928B2 (en) * 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
GB9022785D0 (en) 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (en) 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
CN1041931C (zh) 1993-05-06 1999-02-03 诺沃-诺迪斯克有限公司 [1,2,4]三唑并[4,3－a]喹喔啉化合物,它们的制备及其应用
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
KR100358636B1 (ko) 1997-02-28 2002-10-31 화이자 프로덕츠 인코포레이티드 3-아릴-4(3에이치)-퀴나졸리논의 회전장애이성질체 및 에이엠피에이-수용체 길항물질로서 그의 용도

Also Published As

Publication number Publication date
CZ352698A3 (cs) 1999-11-17
AU1554997A (en) 1997-12-05
HRP970261A2 (en) 2000-12-31
HUP9902148A3 (en) 2002-11-28
GT199700049A (es) 1998-10-21
AR007118A1 (es) 1999-10-13
HN1997000052A (es) 1997-06-26
CN1420114A (zh) 2003-05-28
HUP9902148A2 (hu) 2000-04-28
EA002905B1 (ru) 2002-10-31
PL330042A1 (en) 1999-04-26
DE69722613D1 (de) 2003-07-10
CA2252907A1 (en) 1997-11-20
YU19197A (sh) 1999-09-27
BG102999A (en) 1999-09-30
EP0901487A1 (en) 1999-03-17
KR100375155B1 (ko) 2003-08-19
SK284108B6 (sk) 2004-09-08
HK1019607A1 (en) 2000-02-18
NO985293L (no) 1999-01-13
EA199800923A1 (ru) 1999-06-24
TR199802296T2 (xx) 1999-02-22
DE69722613T2 (de) 2004-05-13
ZA974156B (en) 1998-11-16
NO985293D0 (no) 1998-11-13
SI0901487T1 (en) 2003-10-31
TW539675B (en) 2003-07-01
BR9709085A (pt) 1999-08-03
MA26430A1 (fr) 2004-12-20
US6303615B1 (en) 2001-10-16
CA2252907C (en) 2005-05-17
PT901487E (pt) 2003-08-29
ATE242232T1 (de) 2003-06-15
IL126589A0 (en) 1999-08-17
WO1997043276A1 (en) 1997-11-20
CN1218464A (zh) 1999-06-02
JPH11514663A (ja) 1999-12-14
JP3241388B2 (ja) 2001-12-25
DZ2237A1 (fr) 2002-12-03
IL126589A (en) 2003-06-24
TNSN97087A1 (fr) 2005-03-15
SK152098A3 (en) 2000-05-16
HRP970261B1 (en) 2003-06-30
IS4881A (is) 1998-10-27
DK0901487T3 (da) 2003-08-25
AP9701003A0 (en) 1997-07-31
ES2198546T3 (es) 2004-02-01
CZ295565B6 (cs) 2005-08-17
EP0901487B9 (en) 2004-09-29
EP0901487B1 (en) 2003-06-04
AU730503B2 (en) 2001-03-08
CN1103772C (zh) 2003-03-26
KR20000011054A (ko) 2000-02-25
AP1148A (en) 2003-02-28
OA10918A (en) 2001-10-25

Similar Documents

Publication Publication Date Title
ID17149A (id) Senyawa baru 2,3 tersubstitusi-4 (3h)-kuinazolinon
ID21881A (id) Turunan-turunan baru pirazol tersubstitusi
ID17686A (id) Fotoinisiator alpha-aminoasetofenon baru
IS4970A (is) Setnar 6,6-heteró-bísýklískar afleiður
ID15840A (id) Turunan-turunan 19-nor-pregnena baru
TR199600096A2 (tr) Yeni bilesikler.
TR199700090A2 (tr) Yeni heteroaril-oksazolidinonlar.
TR199501597A2 (tr) Yeni bilesikler.
TR199501655A2 (tr) Yeni monosiklik -laktam bilesikleri.
ID16298A (id) Turunan-turunan 1,2,3,4-tetrahidronaftalena yang disubstitusi
DE59507222D1 (de) Substituierte 1,2,3,4-tetrahydro-5-nitro-pyrimidine
ID18431A (id) Senyawa-senyawa baru
ID16660A (id) Senyawa-senyawa b-laktam monosiklik baru
ID17421A (id) Senyawa senyawa baru
BR9609884A (pt) N-aril- 1,2,4-triazolin-5-onas
DE69618634D1 (de) 1,4-benzodioxin-derivate
ID16778A (id) Turunan 2-(3h)-okasazolon baru
ID18262A (id) Turunan-turunan baru piranosida
ID19433A (id) Senyaw-senyawa baru
ID16684A (id) Senyawa-senyawa sulfonilurea baru
ID18889A (id) Senyawa baru
ID22144A (id) Senyawa-senyawa baru
ID16373A (id) Senyawa-senyawa baru
NO973624L (no) Vasokonstriktive substituerte 2,3-dihydro-1,4-dioksinopiperidiner
ID17265A (id) Herbisida-herbisida baru